Is BIODESIX INC (BDSX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 41.3% / 30% | 17.5% / 30% | 5.7% / 30% | 0.58% / 5% | ✗ NOT HALAL |
| DJIM | 41.3% / 33% | 17.5% / 33% | 5.7% / 33% | 0.58% / 5% | ✗ NOT HALAL |
| MSCI | 63.7% / 33% | 27.0% / 33% | 8.8% / 33% | 0.58% / 5% | ✗ NOT HALAL |
| S&P | 41.3% / 33% | 17.5% / 33% | 5.7% / 33% | 0.58% / 5% | ✗ NOT HALAL |
| FTSE | 63.7% / 33% | 27.0% / 33% | 8.8% / 50% | 0.58% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 81.1% | |
| Operating Margin | -6.8% | |
| Net Margin | -39.8% | |
| Return on Equity (ROE) | -383.1% | |
| Return on Assets (ROA) | -18.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$23M |
| Free Cash Flow | -$24M |
| Total Debt | $73M |
| Current Ratio | 1.9 |
| Total Assets | $87M |
Price & Trading
| Last Close | $14.60 |
| 50-Day MA | $13.31 |
| 200-Day MA | $8.82 |
| Avg Volume | 1.5M |
| Beta | 0.6 |
|
52-Week Range
$3.44
| |
About BIODESIX INC (BDSX)
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BIODESIX INC (BDSX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BIODESIX INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BIODESIX INC's debt ratio?
BIODESIX INC's debt ratio is 41.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 63.7%.
What are BIODESIX INC's key financial metrics?
BIODESIX INC has a market capitalization of $140M, and revenue of $88M. The company maintains a gross margin of 81.1% and a net margin of -39.8%. Return on equity stands at -383.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.